What does this research mean for the field?

The cannabinoid receptor agonists ACEA and WIN 55,212-2 mesylate exert anti-proliferative effects on neuroblastoma and glioblastoma cells via CB1 receptors, but their combination with temozolomide often produces antagonistic interactions, whereas WIN 55,212-2 mesylate synergizes with cisplatin in neuroblastoma cells. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

To assess the anti-proliferative interactions of cannabinoid receptor agonists ACEA and WIN 55,212-2 mesylate combined with cisplatin or temozolomide across neuroblastoma and glioblastoma cell lines.

September 10, 2026Pharmacological ReportsOpen Access

Interactions of ACEA and WIN 55,212-2 mesylate with temozolomide and cisplatin in neuroblastoma and glioblastoma cell lines: an isobolographic analysis

View Full Paper

Ask AI

Bookmark

Authors

KZKatarzyna Załuska-Ogryzek PWPaula Wróblewska-Łuczka AGAgnieszka Góralczyk

Discussion

Member takes

Overview

In vitro study demonstrates distinct synergistic and antagonistic interactions of cannabinoids with chemotherapy in brain cancer cell lines, suggesting caution with specific drug combinations.

Key Points

To assess the anti-proliferative interactions of cannabinoid receptor agonists ACEA and WIN 55,212-2 mesylate combined with cisplatin or temozolomide across neuroblastoma and glioblastoma cell lines.
Measured cell viability and proliferation in CHP-134, KELLY, U-87MG, T98G, and C6 lines using MTT, LDH, and BrdU assays.
Performed isobolographic analysis of 1:1 fixed-ratio combinations of cannabinoids with cisplatin or temozolomide.
Evaluated CB1 receptor, Bax, and Bcl-2 protein expression via Western blot and tested CB1 mediation using the antagonist AM281.
WIN 55,212-2 combined with cisplatin exerted a synergistic interaction in CHP-134 cells (p < 0.05) and additive interactions in the remaining four cell lines, whereas ACEA plus cisplatin exerted additive interactions across all lines.
Cannabinoid combinations with temozolomide produced antagonism: ACEA was antagonistic in CHP-134 (p < 0.05) and C6 (p < 0.0001), while WIN 55,212-2 was antagonistic in KELLY (p < 0.05), T98G (p < 0.01), and C6 (p < 0.01).
Pre-incubation with the CB1 antagonist AM281 significantly attenuated the anti-viability actions of both agonists at 24, 48, and 72 h, whereas Bax and Bcl-2 proteins showed no involvement.

Cite This Study

Załuska-Ogryzek et al. (2026) studied this question.

synapsesocial.com/papers/6aa27b6f58559d80afc74b63 https://doi.org/10.1007/s43440-026-00898-8

View Full Paper

Ask AI

Bookmark

September 10, 2026Pharmacological ReportsOpen Access

Interactions of ACEA and WIN 55,212-2 mesylate with temozolomide and cisplatin in neuroblastoma and glioblastoma cell lines: an isobolographic analysis

View Full Paper

Ask AI

Bookmark

Authors

KZKatarzyna Załuska-Ogryzek PWPaula Wróblewska-Łuczka AGAgnieszka Góralczyk

Discussion

Member takes

Overview

In vitro study demonstrates distinct synergistic and antagonistic interactions of cannabinoids with chemotherapy in brain cancer cell lines, suggesting caution with specific drug combinations.

Key Points

To assess the anti-proliferative interactions of cannabinoid receptor agonists ACEA and WIN 55,212-2 mesylate combined with cisplatin or temozolomide across neuroblastoma and glioblastoma cell lines.
Measured cell viability and proliferation in CHP-134, KELLY, U-87MG, T98G, and C6 lines using MTT, LDH, and BrdU assays.
Performed isobolographic analysis of 1:1 fixed-ratio combinations of cannabinoids with cisplatin or temozolomide.
Evaluated CB1 receptor, Bax, and Bcl-2 protein expression via Western blot and tested CB1 mediation using the antagonist AM281.
WIN 55,212-2 combined with cisplatin exerted a synergistic interaction in CHP-134 cells (p < 0.05) and additive interactions in the remaining four cell lines, whereas ACEA plus cisplatin exerted additive interactions across all lines.
Cannabinoid combinations with temozolomide produced antagonism: ACEA was antagonistic in CHP-134 (p < 0.05) and C6 (p < 0.0001), while WIN 55,212-2 was antagonistic in KELLY (p < 0.05), T98G (p < 0.01), and C6 (p < 0.01).
Pre-incubation with the CB1 antagonist AM281 significantly attenuated the anti-viability actions of both agonists at 24, 48, and 72 h, whereas Bax and Bcl-2 proteins showed no involvement.

Cite This Study

Załuska-Ogryzek et al. (2026) studied this question.

synapsesocial.com/papers/6aa27b6f58559d80afc74b63 https://doi.org/10.1007/s43440-026-00898-8

View Full Paper

Ask AI

Bookmark